Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimozide in ALS
NCT02463825Phase 2Unknown
- Sponsor
- University of Calgary
- Start
- Apr 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pimozide in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by University of Calgary. Primary endpoints: ALS Functional Rating Scale-Revised at Day 65, Slow Vital Capacity at Day 65 and 1 more. Status: unknown.
02
Drugs
pimozide
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02463825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02463825.